Docetaxel

CAT: 0804-HY-B0011-01Size: 100 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0011-01Size:100 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity[1][3].
CAS Number
[114977-28-5]
Product Name Alternative
RP-56976
UNSPSC
12352005
Hazard Statement
H315, H319, H341, H360, H362, H372
Target
Apoptosis; Endogenous Metabolite; Microtubule/Tubulin
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Docetaxel.html
Purity
99.94
Solubility
DMSO : 100 mg/mL (ultrasonic) |Ethanol : 50 mg/mL (ultrasonic)
Smiles
O=C(OC(C)(C)C)N[C@@H](C1=CC=CC=C1)[C@H](C(O[C@@H]2C(C)=C([C@@H](O)C([C@@]3(C)[C@]([C@@](CO4)(OC(C)=O)[C@@]4([H])C[C@@H]3O)([H])[C@@H]5OC(C6=CC=CC=C6)=O)=O)C(C)(C)[C@@]5(O)C2)=O)O
Molecular Formula
C43H53NO14
Molecular Weight
807.88
Precautions
H315, H319, H341, H360, H362, H372
References & Citations
[1]Attia RT, et al. The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells. PeerJ. 2016 Jun 29;4:e2168.|[2]Che CL, et al. DNA microarray reveals different pathways responding to NSC 125973 and docetaxel in non-small cell lung cancer cell line. Int J Clin Exp Pathol. 2013 Jul 15;6 (8) :1538-48.|[3]Obi-Ioka Y, et al. Involvement of Wee1 in the circadian rhythm dependent intestinal damage induced by docetaxel. J Pharmacol Exp Ther. 2013 Oct;347 (1) :242-8.|[4]Li C, et al. Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. J Pharm Biomed Anal. 2016 Sep 5;128:286-93.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
ACS Appl Mater Interfaces. 2023 May 3;15 (17) :20697-20711.|ACS Appl Mater Interfaces. 2024 Sep 25;16 (38) :50147-50159.|ACS Nano. 2021 Apr 27;15 (4) :7179-7194.|ACS Omega. 2024 Feb 28;9 (10) :11870-11882.|ACS Sens. 2023 Feb 24;8 (2) :543-554.|Acta Pharm Sin B. 2021 Apr;11 (4) :1069-1082.|Adv Funct Mater. 2023 Dec 15.|Adv Mater. 2025 Jul 4:e2505231.|Adv Sci (Weinh) . 2024 Nov 20:e2407662.|Anticancer Drugs. 2022 Oct 1;33 (9) :871-882.|Arch Biochem Biophys. 2023 Mar 15:737:109551.|Arch Pharm Res. 2024 Nov;47 (10-11) :829-853.|Biochem Biophys Rep. 2024 Jan 14:37:101639.|Biochem Pharmacol. 2020 May;175:113865.|Biochim Biophys Acta Mol Cell Res. 2025 Jul 31;1872 (8) :120029.|Biofabrication. 2023 Jun 9;15 (3) .|Biol Direct. 2024 Sep 11;19 (1) :79.|Biomark Res. 2022 Jul 13;10 (1) :48.|Biomaterials. 2022 Oct:289:121783.|Biomed Chromatogr. 2022 Sep;36 (9) :e5417.|Biomed Pharmacother. 2023 Jul:163:114751.|Biomed Pharmacother. 2023 Sep:165:115023.|bioRxiv. 2023 Nov 1:2023.10.29.564598.|bioRxiv. 2025 Jan 24:2025.01.22.632572.|bioRxiv. 2025 Sep 21.|BJU Int. 2025 Nov 3.|BMC Cancer. 2025 Jul 1;25 (1) :1042.|Breast Cancer Res Treat. 2023 Jul;200 (2) :193-201.|Breast Cancer Res. 2024 Mar 19;26 (1) :48.|Breast Cancer. 2024 Dec 20:16:993-1004.|Cancer Cell Int. 2024 Dec 27;24 (1) :433.|Cancer Cell Int. 2024 Jul 17;24 (1) :249.|Cancer Immunol Immunother. 2025 Nov 18;74 (12) :377.|Cancer Immunol Res. 2023 May 3;11 (5) :583-599.|Cancer Lett. 2023 Sep 1:571:216338.|Cancer Lett. 2024 Nov 26:217339.|Cancer Res. 2025 Oct 9.|Cancer Sci. 2024 Feb;115 (2) :412-426.|Cancers. 2020 Jul 28;12 (8) :2092.|Cell Biosci. 2023 Nov 25;13 (1) :215.|Cell Death Dis. 2024 Aug 7;15 (8) :571.|Cell Death Dis. 2025 Mar 12;16 (1) :170.|Cell Mol Gastroenterol Hepatol. 2021;11 (3) :683-696.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep. 2024 Jul 3;43 (7) :114431.|Chem Biol Drug Des. 2025 Feb;105 (2) :e70053.|Chem Biol Interact. 2023 Mar 1:373:110372.|Clin Epigenetics. 2025 May 6;17 (1) :77.|Clin Transl Oncol. 2022 Nov;24 (11) :2231-2240.|Diabetes. 2023 Jan 1;72 (1) :97-111.|Discov Oncol. 2023 May 27;14 (1) :82.|Drug Deliv Transl Res. 2021 Oct;11 (5) :2030-2051.|Eur J Histochem. 2022 Oct 25;66 (4) .|Eur J Med Chem. 2018 Feb 25:146:157-170.|Eur J Med Res. 2025 Aug 4;30 (1) :704.|Eur Urol. 2020 Nov 2; S0302-2838 (20) 30778-8.|FEBS J. 2024 Jul;291 (14) :3249-3266.|Front Biosci (Landmark Ed) . 2025 Feb 20;30 (2) :25522.|Front Oncol. 2019 Dec 19;9:1398.|Genome Med. 2024 Jan 12;16 (1) :11.|Int J Cancer. 2024 Jul 15;155 (2) :324-338.|Int J Clin Exp Pathol. 2017;10 (3) :3033-3042.|Int J Mol Med. 2024 Jul;54 (1) :60.|Int J Mol Sci. 2019 Jan; 20 (1) : 28.|Int J Mol Sci. 2022 Nov 19;23 (22) :14385.|Int J Pharm. 2023 Apr 5:636:122846.|iScience. 2025 Oct 30;28 (12) :113908.|iScience. 2025 Sep 9;28 (10) :113520.|J Agric Food Chem. 2024 Jul 31;72 (30) :16801-16811.|J Appl Polym Sci. 18 February 2022.|J Biol Chem. 2021 Jan-Jun:296:100276.|J Cancer Res Clin Oncol. 2022 Dec;148 (12) :3511-3520.|J Cell Mol Med. 2022 Apr;26 (8) :2392-2403.|J Colloid Interface Sci. 2022 May 2;622:789-803.|J Control Release. 2021 Jan 10;329:847-857.|J Control Release. 2023 Jan:353:490-506.|J Control Release. 2024 Dec:376:829-841.|J Exp Clin Cancer Res. 2023 Aug 18;42 (1) :209.|J Hematol Oncol. 2023 May 3;16 (1) :46.|J Immunother Cancer. 2021 Jul;9 (7) :e001758.|J Liposome Res. 2020 Jun;30 (2) :182-196.|J Microencapsul. 2019 Sep;36 (6) :552-565.|J Microencapsul. 2020 Dec;37 (8) :543-556.|J Oncol. 2022 Mar 10:2022:9055954.|Life Sci. 2020 Sep 1;256:117983.|Life Sci. 2021 Jan 1;264:118674.|Life Sci. 2025 Apr 17:372:123646.|Mater Sci Eng C Mater Biol Appl. 2021 Apr:123:111956.|Materials. 2020 Mar 2;13 (5) :1099.|Microchem J. 2025 Oct 15;218:115702.|Mol Biol Res Commun. 2022 Mar;11 (1) :11-20.|Mol Cancer. 2024 May 9;23 (1) :83.|Mol Carcinog. 2025 Jan;64 (1) :192-208.|Mol Med Rep. 2020 Jul;22 (1) :67-76.|Nanotheranostics. 2021 Jan 1;5 (2) :143-154.|Nanotheranostics. 2021; 5 (2) : 143-154.|Oncogene. 2025 Nov;44 (45) :4405-4412.|Oncol Lett. 2022 Mar;23 (3) :101.|Oncotarget. 2016 May 17;7 (20) :28891-902.|Oncotarget. 2017 Dec 2;8 (68) :112313-112329.|Oxid Med Cell Longev. 2022 May 24:2022:4930643.|Patent. US20230145200A1.|Pathol Res Pract. 2025 Sep:273:156138.|Pharm Dev Technol. 2021 Oct;26 (8) :910-921.|Pharm Res. 2025 Nov 18.|Pharmaceuticals (Basel) . 2024 Apr 29;17 (5) :569.|Pharmacol Res. 2024 May 9:204:107208.|Phytomedicine. 2022 May:99:153939.|Phytomedicine. 2023 Aug:117:154921.|Phytomedicine. 2023 Jan:109:154584.|Phytomedicine. 2024 Dec:135:156155.|PLoS Genet. 2025 Mar 31;21 (3) :e1011652.|Preprints. 2023 Jul 13.|Proc Natl Acad Sci U S A. 2023 Apr 25;120 (17) :e2218522120.|Reprod Toxicol. 2026 Jan:139:109110.|Res Sq. 2025 May 16:rs.3.rs-6590535.|Res Sq. 2025 Sep 7.|Research Square Preprint. 2021 Jan.|Research Square Print. November 29th, 2022.|Sci Rep. 2023 Jun 3;13 (1) :9043.|Sci Rep. 2024 Mar 27;14 (1) :7303.|Sci Rep. 2025 Jul 4;15 (1) :23847.|Sci Transl Med. 2024 Apr 3;16 (741) :eadj5705.|Seoul National University. Molecular medicine and Biopharmaceutical sciences. 2021 Dec.|Signal Transduct Target Ther. 2022 Sep 12;7 (1) :317.|SSRN. 2024 Mar 22.|SSRN. 2025 Jun 4.|Transl Lung Cancer Res. 2024 Oct 31;13 (10) :2698-2712.|Transl Oncol. 2023 Sep:35:101723.|University of Adelaide. 2023 Jan.|University of Beirut. 2025.|University of Granada. 2025.|University of Minnesota. 2024.|bioRxiv. 2025 June 01.|Br J Pharmacol. 2024 Nov;181 (21) :4279-4293.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|J Pharm Investig. 2025 Sep 19.

Related Products

CatalogName
HY-B0018-01Docetaxal

Alternative Products

CatalogName
M10528-01Docetaxel

Popular Products